While thousands of Actos bladder cancer cases were included in the $2.4 Billion 2015 settlement, potentially hundreds if not thousands of additional victims have been diagnosed with bladder cancer since who would not have qualified to be part of the previous settlement and were taking Actos prior to it being linked to bladder cancer. For these victims, additional settlements may be upcoming.
Actos is a Type II Diabetes drug prescribed to help lower blood sugar levels by making the body more sensitive to insulin. Actos, which has the generic name “pioglitazone,” was released by Takeda Pharmaceuticals in 1999. It was aggressively marketed by partner Eli Lily as a safe, effective Type II Diabetes medication. Over a decade, Actos became on of the most popular diabetes medications of all time, grossing nearly $3.6 billion, which accounted for over a quarter of Takeda’s revenue at the time.
Actos has been linked to an increased risk of bladder cancer. It is believed that Takeda knew of risks associated with the drug before it was released. Lawsuits claim that their failure to warn the public was negligent and dangerous; Takeda’s inaction has impacted many people’s lives.